Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Carmen Escuriola, Robert F. Sidonio, Jr.

Blood (2024) 144 (Supplement 1): 5475.

https://doi.org/10.1182/blood-2024-193874

Published: 2024

Journal Articles

Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study

Cedric Hermans, Cihan Ay, Carmen Escuriola, Peter Kampmann, Rikke Medom Meldgaard, Ilgiz Rakhmatullin, Ciprian Tomuleasa, Lize Fie Ditteke van Vulpen, Michael Wang, Irena Woźnica-Karczmarz, Sophie Susen

Blood (2024) 144 (Supplement 1): 1212.

https://doi.org/10.1182/blood-2024-198395

Published: 2024

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Robert Klamroth, Karin Kurnik, Swee Wenning, Carmen Escuriola-Ettingshausen, Stephan Regensburger, Leilei Tang, Joan Gu, Randy Guerra, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2021-146162

Published: 2021

Journal Articles

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Cedric Hermans, MDMRCP,PhD, Claude Négrier, Pål A Holme, Carmen Escuriola, Ana R Cid, Nataliya Kemenyash, MSc, Jaco Botha, Viridiana Cano-Garcia, Jerzy Windyga

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139298

Published: 2020

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Manuel Carcao, MD, Maria L. Avila, MD, Victor S. Blanchette, MD FRCP, Elena Santagostino, MD PhD, Carmen Escuriola-Ettingshausen, MD PhD, Cindy A. Leissinger, MD, Thierry Lambert, Louis M. Aledort, MD

Blood (2015) 126 (23): 3535.

https://doi.org/10.1182/blood.V126.23.3535.3535

Published: 2015

Journal Articles

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Jan Astermark, Paul P. Brons, Giancarlo Castaman, Marjon H. Cnossen, Natasja Dors, Carmen Escuriola-Ettingshausen, Karly Hamulyak, Daniel P. Hart, Charles R. M. Hay, Saturnino Haya, Waander L. van Heerde, Cedric Hermans, Margareta Holmström, Victor Jimenez-Yuste, Russell D. Keenan, Robert Klamroth, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Ri Liesner, Anne Mäkipernaa, Christoph Male, Evelien Mauser-Bunschoten, Maria G. Mazzucconi, Simon McRae, Karina Meijer, Michael Mitchell, Massimo Morfini, Marten Nijziel, Johannes Oldenburg, Kathelijne Peerlinck, Pia Petrini, Helena Platokouki, Sylvia E. Reitter-Pfoertner, Elena Santagostino, Piercarla Schinco, Frans J. Smiers, Berthold Siegmund, Annarita Tagliaferri, Thynn T. Yee, Pieter Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat

Blood (2013) 122 (11): 1954–1962.

https://doi.org/10.1182/blood-2013-02-483263

Published: 2013

Includes: Supplemental data

Journal Articles

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

Gili Kenet, MD, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, MD, Sven Gutsche, MD, Susan Halimeh, MD, Verena Janssen, MD, Karin Kurnik, MD, Ulrike Nowak-Gottl, MD

Blood (2012) 120 (21): 2234.

https://doi.org/10.1182/blood.V120.21.2234.2234

Published: 2012

Journal Articles

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

Carmen Escuriola-Ettingshausen, MD, Vladimir Vdovin, MD, Nadezhda Zozulya, MD, PhD, Olga Plyushch, Prof, Wolfhart Kreuz, MD, Bruce A. Schwartz, PhD

Blood (2011) 118 (21): 3310.

https://doi.org/10.1182/blood.V118.21.3310.3310

Published: 2011

Journal Articles

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Susanne Holzhauer, MD, Christoph Bidlingmaier, MD, Carmen Escuriola Ettingshausen, MD, Susan Halimeh, MD, Alfonso Iorio, MD, Gili Kenet, MD, Brigitte Pautard, MD, Ulrike Nowak-Gottl, MD

Blood (2010) 116 (21): 710.

https://doi.org/10.1182/blood.V116.21.710.710

Published: 2010

Journal Articles

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Karin Kurnik, MD, Susan Halimeh, MD, Daniela Manner, MD, Susanne Holzhauer, MD, Carmen Escuriola Ettingshausen, MD, Rosemarie Schobess, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 1303.

https://doi.org/10.1182/blood.V114.22.1303.1303

Published: 2009

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Rosemarie Schobess, Karin Kurnik, Wolfhart Kreuz, Frauke Friedrichs, Anne Krumpel, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Ulrike Nowak-Gottl

Blood (2007) 110 (11): 3146.

https://doi.org/10.1182/blood.V110.11.3146.3146

Published: 2007

Journal Articles

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

Samantha C. Gouw, Johanna G. van der Bom, Günter Auerswald, Carmen Escuriola Ettinghausen, Ulf Tedgård, H. Marijke van den Berg

Blood (2007) 109 (11): 4693–4697.

https://doi.org/10.1182/blood-2006-11-056317

Published: 2007

Includes: Supplemental data

Journal Articles

Immune Tolerance Induction (ITI) in Hemophilia A and Inhibitors using VWF Containing Factor VIII Concentrates.

Wolfhart Kreuz, MD, Carmen Escuriola Ettingshausen, MD, Guenter K.H. Auerswald, MD, Hans Herrmann Brackmann, MD, Thomas Klingebiel, MD

Blood (2004) 104 (11): 3092.

https://doi.org/10.1182/blood.V104.11.3092.3092

Published: 2004

Journal Articles

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Ulrike Nowak-Gottl, MD, Carmen Escuriola, MD, Rosemarie Schobess, MD, Christine Duering, MD, Christoph Bidlingmaier, MD, Hartmut Pollmann, MD, Sylvia Horneff, MD, Karin Kurnik, MD

Blood (2004) 104 (11): 3095.

https://doi.org/10.1182/blood.V104.11.3095.3095

Published: 2004

NARROW

Strategies for Immune Tolerance Induction in Hemophilia a Patients with Inhibitors: The First Prespecified Interim Analysis from the Motivate Study

Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

Immune Tolerance Induction (ITI) in Hemophilia A and Inhibitors using VWF Containing Factor VIII Concentrates.

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only